Publication

Single-Cell RNA Sequencing Reveals Distinct Cardiac-Derived Stromal Cell Subpopulations

Downloadable Content

Persistent URL
Last modified
  • 07/03/2025
Type of Material
Authors
    Jessica R Hoffman, Georgia Institute of TechnologyArun R Jayaraman, Georgia Institute of TechnologySruti Bheri, Georgia Institute of TechnologyMichael Davis, Emory University
Language
  • English
Date
  • 2022-11-01
Publisher
  • MDPI
Publication Version
Copyright Statement
  • © 2022 by the authors.
License
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 9
Issue
  • 11
Grant/Funding Information
  • This work was also supported by funding from Additional Ventures as part of the Cures Collaborative.
  • This work was supported by grants from the National Institute of Health (R01HL145644 to M.E.D.; F31HL154725 and T32GM008602 to J.R.H.).
Supplemental Material (URL)
Abstract
  • Human cardiac-derived c-kit+ stromal cells (CSCs) have demonstrated efficacy in preclinical trials for the treatment of heart failure and myocardial dysfunction. Unfortunately, large variability in patient outcomes and cell populations remains a problem. Previous research has demonstrated that the reparative capacity of CSCs may be linked to the age of the cells: CSCs derived from neonate patients increase cardiac function and reduce fibrosis. However, age-dependent differences between CSC populations have primarily been explored with bulk sequencing methods. In this work, we hypothesized that differences in CSC populations and subsequent cell therapy outcomes may arise from differing cell subtypes within donor CSC samples. We performed single-cell RNA sequencing on four neonatal CSC (nCSC) and five child CSC (cCSC) samples. Subcluster analysis revealed cCSC-enriched clusters upregulated in several fibrosis- and immune response-related genes. Module-based analysis identified upregulation of chemotaxis and ribosomal activity-related genes in nCSCs and upregulation of immune response and fiber synthesis genes in cCSCs. Further, we identified versican and integrin alpha 2 as potential markers for a fibrotic cell subtype. By investigating differences in patient-derived CSC populations at the single-cell level, this research aims to identify and characterize CSC subtypes to better optimize CSC-based therapy and improve patient outcomes.
Author Notes
Keywords
Research Categories
  • Engineering, Biomedical

Tools

Relations

In Collection:

Items